PLS3 expression and SMA phenotype: a commentary on correlation of PLS3 expression with disease severity in children with spinal muscular atrophy

被引：2
|
作者：
Nishio, Hisahide [1 ]
机构：
[1] Kobe Univ, Grad Sch Med, Dept Community Med & Social Healthcare Sci, Kobe, Hyogo 657, Japan
来源：
JOURNAL OF HUMAN GENETICS | 2014年 / 59卷 / 02期
关键词：
D O I：
10.1038/jhg.2013.124
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：64 / 65
页数：2
相关论文
共 44 条
  • [21] SMNT and NAIP mutations in Canadian families with spinal muscular atrophy (SMA): Genotype/phenotype correlations with disease severity
    Simard, LR
    Rochette, C
    Semionov, A
    Morgan, K
    Vanasse, M
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1997, 72 (01): : 51 - 58
  • [22] Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease)
    Salort-Campana, E.
    Quijano-Roy, S.
    ARCHIVES DE PEDIATRIE, 2020, 27 (07): : 23 - 28
  • [23] Nusinersen in Symptomatic Children with Later-onset Spinal Muscular Atrophy (SMA): Design of the Phase 3 CHERISH Study
    Schneider, Eugene
    Mignon, Laurence
    Su, John
    Baldwin, Ron
    Bishop, Kathie
    Zhong, Zhenshao John
    Farwell, Wildon
    Bennett, C. Frank
    NEUROLOGY, 2017, 88
  • [24] Decreased expression of full-length mRNA for (c)BCD541 does not correlate with spinal muscular atrophy phenotype severity
    Nishio, H
    Ishikawa, Y
    Lee, MJ
    Fujii, M
    Kanda, F
    Jinnai, K
    Takahashi, K
    Takeshima, Y
    Wada, H
    Takada, S
    Nakamura, H
    Matsuo, M
    Sumino, K
    NEUROLOGY, 1997, 48 (05) : 1266 - 1270
  • [25] The effect of nusinersen on function and muscle strength in the upper limb in a cohort of children with spinal muscular atrophy (SMA) type 2 and 3
    Milev, E.
    Wolfe, A.
    Main, M.
    Baranello, G.
    Scoto, M.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S90 - S91
  • [26] FUS protein expression in the myopathology of 5q-associated spinal muscular atrophy type 3
    Koelbel, H.
    Dobelman, V.
    van Haute, L.
    Lancene, E.
    Kollipara, L.
    Della Marina, A.
    Horvath, R.
    Schara-Schmidt, U.
    Ruck, T.
    Schoser, B.
    Evangelista, T.
    Roos, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [27] A patient with both Charcot-Marie-Tooth-disease (CMT 1A) and mild spinal muscular atrophy (SMA 3)
    Jedrzejowska, Maria
    Ryniewicz, Barbara
    Kabzinska, Dagmara
    Drac, Hanna
    Hausmanowa-Petrusewicz, Irena
    Kochanski, Andrzej
    NEUROMUSCULAR DISORDERS, 2008, 18 (04) : 339 - 341
  • [28] Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study
    Finkel, Richard
    Mercuri, Eugenio
    Kirschner, Jan
    Chiriboga, Claudia A.
    Kuntz, Nancy
    Darras, Basil T.
    Shieh, Perry B.
    Saito, Kayoko
    De Vivo, Darryl
    Day, John W.
    Mazzone, Elena S.
    Montes, Jacqueline
    Yang, Qingqing
    Zhong, Zhenshao John
    Gheuens, Sarah
    Bennett, C. Frank
    Schneider, Eugene
    Farwell, Wildon
    NEUROLOGY, 2017, 89 (08) : E100 - E101
  • [29] MODEL-BASED INVESTIGATION OF CYP3A ENZYME INACTIVATION EFFECT OF RISDIPLAM IN INFANTS, CHILDREN, AND ADULTS WITH SPINAL MUSCULAR ATROPHY (SMA).
    Cleary, Y.
    Gertz, M.
    Grimsey, P.
    Guenther, A.
    Heinig, K.
    Ogungbenro, K.
    Aarons, L.
    Galetin, A.
    Kletzl, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S9 - S10
  • [30] The expression of SMN1, MART3, GLE1 and FUS genes in spinal muscular atrophy
    Alrafiah, Aziza
    Alghanmi, Maimonah
    Almashhadi, Sufana
    Aqeel, Aqeel
    Awaji, Adel
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2018, 56 (04) : 215 - 221
12345